1. Home
  2. SPRO vs GLED Comparison

SPRO vs GLED Comparison

Compare SPRO & GLED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.20

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

GLED

GalaxyEdge Acquisition Corporation Ordinary Shares

N/A

Current Price

$9.96

Market Cap

159.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
GLED
Founded
2013
N/A
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
159.0M
IPO Year
2017
2026

Fundamental Metrics

Financial Performance
Metric
SPRO
GLED
Price
$1.20
$9.96
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.0M
72.0K
Earning Date
05-13-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$9.94
52 Week High
$3.08
$9.98

Technical Indicators

Market Signals
Indicator
SPRO
GLED
Relative Strength Index (RSI) 22.37 53.85
Support Level N/A $9.95
Resistance Level $2.44 $9.98
Average True Range (ATR) 0.16 0.00
MACD -0.05 0.00
Stochastic Oscillator 10.32 50.00

Price Performance

Historical Comparison
SPRO
GLED

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About GLED GalaxyEdge Acquisition Corporation Ordinary Shares

GalaxyEdge Acquisition Corp is a newly organized blank check company. The company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

Share on Social Networks: